Report of Foreign Issuer (6-k)
June 14 2018 - 5:28PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of:
June 2018 (Report No. 2)
Commission
file number:
001- 38041
THERAPIX
BIOSCIENCES LTD.
(Translation
of registrant’s name into English)
4
Ariel Sharon Street
HaShahar
Tower, 16th Floor
Givatayim
5320047, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
On
June 11, 2018, Mark Groussman resigned from his position as a member of the Board of Directors (the “Board”) of Therapix
Biosciences Ltd. (the “Company”). Mr. Groussman’s resignation was not related to any disagreement with the Board
on any matter relating to the operations, policies or practices of the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Therapix
Biosciences Ltd.
(Registrant)
|
|
|
|
|
By
|
/s/
Ascher Shmulewitz
|
|
Name:
|
Ascher
Shmulewitz, M.D, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Date:
June 14, 2018
2
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024